Recent medical and scientific developments span regulatory trial holds on investigational epilepsy treatments, newly discovered imaging links between liver enzymes and cognitive decline in Alzheimer’s research, and prestigious honors for landmark brain and sleep science discoveries, according to recent scientific reporting and clinical journal studies.
Regulatory Trial Hold on Investigational Epilepsy Drug BHV-7000
Federal regulators have intervened in ongoing clinical development for an emerging neurological treatment. The regulatory pause was triggered by metabolite findings observed in rodent tests.
Biomarkers, Brain Aging, and Cognitive Decline in Alzheimer’s Research
Recent clinical studies continue to refine how researchers track and understand neurological deterioration. Baseline aspartate aminotransferase-to-alanine aminotransferase ratios were linked with faster cognitive and cortical decline in 2,700 Alzheimer’s Disease Neuroimaging Initiative participants, particularly among APOE4 carriers, as detailed in findings published in Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring.
Additional imaging research highlights broader physiological connections to neurological health. Brain-gut crosstalk was associated with brain aging in healthy young and midlife adults, according to an imaging evaluation of four cohorts published in eBioMedicine. Concurrently, a sample of social media posts concerning Alzheimer’s blood tests revealed that more than a third of users discussed their utility for asymptomatic screening—an application inconsistent with current clinical guidelines, as noted in research from the Journal of the American Geriatrics Society.
Lasker Awards Honor Foundational Brain Science and Sleep Research
While clinical trials face regulatory scrutiny, the broader neuroscientific community continues to celebrate historical and ongoing breakthroughs that shaped modern pharmacology. Lasker Award-winning sleep researchers illustrated how convergent approaches from their laboratories identified the orexin system as an essential wake-promoting neurotransmitter, as described in coverage published in JAMA.
That lineage of foundational discovery stretches back decades across multiple scientific disciplines.
Baulcombe’s academic career includes doctoral studies at the University of Edinburgh completed in 1977, postdoctoral fellowships at McGill University and the University of Georgia, and independent research at the Plant Breeding Institute in Cambridge UK starting in December 1980. He later served as a senior research scientist at the Sainsbury Laboratory in Norwich, professor at the University of East Anglia, and Regius Professor of Botany at the University of Cambridge.